Adaptive 4D volume perfusion CT of lung cancer: Effects of computerized motion correction and the range of volume coverage on measurement reproducibility

American Journal of Roentgenology

Volumn 200, Issue 6, 2013, Pages

  Lee, Sang Min ^a   Lee, Hyun Ju ^a   Kim, Jung Im ^a   Kang, Mi Jin ^b   Goo, Jin Mo ^a   Park, Chang Min ^a   Im, Jung Gi ^a  

^a Seoul National University Hospital   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Lung cancer; Motion correction; Perfusion CT; Reproducibility; Tumor coverage

Indexed keywords

ADAPTIVE FOUR DIMENSIONAL VOLUME PERFUSION COMPUTER ASSISTED TOMOGRAPHY; ADULT; AGED; ARTICLE; BLOOD VOLUME; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; IMAGE PROCESSING; IMAGE QUALITY; LUNG CANCER; MALE; PERMEABILITY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUALITY CONTROL PROCEDURES; REPEAT PROCEDURE; REPRODUCIBILITY; TUMOR BLOOD FLOW; BLOOD FLOW VELOCITY; COMPUTER ASSISTED DIAGNOSIS; COMPUTER PROGRAM; FOUR DIMENSIONAL COMPUTED TOMOGRAPHY; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; MOTION; PROSPECTIVE STUDY; RADIOGRAPHY; VASCULARIZATION; VERY ELDERLY;

CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; IOHEXOL; IOPROMIDE;

AGED; AGED, 80 AND OVER; BLOOD FLOW VELOCITY; BLOOD VOLUME; CONTRAST MEDIA; FEMALE; FOUR-DIMENSIONAL COMPUTED TOMOGRAPHY; HUMANS; IOHEXOL; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOTION; PROSPECTIVE STUDIES; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; REPRODUCIBILITY OF RESULTS; SOFTWARE;

MLCS; MLOWN;

EID: 84880964698     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.12.9458     Document Type: Article

References (20)

1. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-2550
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated nonsmall-cell lung cancer. N Engl J Med 2005; 353:123-132
3. Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247
4. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2:727-739
5. Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003; 21:4428-4438
6. Ng QS, Goh V, Klotz E, et al. Quantitative assessment of lung cancer perfusion using MDCT: does measurement reproducibility improve with greater tumor volume coverage? AJR 2006; 187:1079-1084
7. Ng QS, Goh V, Fichte H, et al. Lung cancer perfusion at multi-detector row CT: reproducibility of whole tumor quantitative measurements. Radiology 2006; 239:547-553
8. Ng CS, Chandler AG, Wei W, et al. Reproducibility of CT perfusion parameters in liver tumors and normal liver. Radiology 2011; 260:762-770
9. Sauter AW, Merkle A, Schulze M, et al. Intraobserver and interobserver agreement of volume perfusion CT (VPCT) measurements in patients with lung lesions. Eur J Radiol 2012; 81:2853-2859
10. Wang J, Wu N, Cham MD, Song Y. Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. AJR 2009; 193:1090-1096
11. Tacelli N, Remy-Jardin M, Copin MC, et al. Assessment of non-small cell lung cancer perfusion: pathologic-CT correlation in 15 patients. Radiology 2010; 257:863-871
12. Fraioli F, Anzidei M, Zaccagna F, et al. Wholetumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenetic chemotherapy: initial experience. Radiology 2011; 259:574-582
13. Ohno Y, Koyama H, Matsumoto K, et al. Differentiation of malignant and benign pulmonary nodules with quantitative first-pass 320-detector row perfusion CT versus FDG PET/CT. Radiology 2011; 258:599-609
14. Spira D, Gerlach JD, Spira SM, Schulze M, Sauter A, Horger M. Effect of scan time on perfusion and flow extraction product (K-trans) measurements in lung cancer using low-dose volume perfusion CT (VPCT). Acad Radiol 2012; 19:78-83
15. Miles KA, Griffiths MR, Fuentes MA. Standardized perfusion value: universal CT contrast enhancement scale that correlates with FDG PET in lung nodules. Radiology 2001; 220:548-553
16. Reiner CS, Goetti R, Eberli D, et al. CT perfusion of renal cell carcinoma: impact of volume coverage on quantitative analysis. Invest Radiol 2012; 47:33-40
17. Saddi KA, Cheriet F. Large deformation registration of contrast-enhanced images with volumepreserving constraint. Abstract In: Proceedings of the International Society for Optical Engineering (SPIE) Conference on Medical Imaging 2007:6512-02
18. Miles KA. Measurement of tissue perfusion by dynamic computed tomography. Br J Radiol 1991; 64:409-412
19. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3:1-7
20. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-310